tetradur la 300
boehringer ingelheim animal health france scs, francúzsko - inj.
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcíny - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
flurbiprofen stada
stada arzneimittel ag, nemecko - flurbiprofén - 69 - otorhinolaryngologica
oroflurb
stada arzneimittel ag, nemecko - flurbiprofén - 69 - otorhinolaryngologica
vocasept 8,75 mg tvrdé pastilky
mapaex consumer healthcare (ireland) private limited, Írsko - flurbiprofén - 69 - otorhinolaryngologica
fungitraxx
avimedical b.v. - itraconazole - antimycotics na systémové použitie, triazole deriváty, itraconazole - vtáčie - na liečbu aspergillosis a kandidózy v spoločník vtákov,.
porcilis pesti
intervet international bv - classical swine fever virus (csfv) -e2 podjednotky antigén - imunologické prístroje pre sviňovité - ošípané - aktívnej imunizácie ošípaných od veku 5 týždňov tehotenstva, aby sa zabránilo úmrtnosti a na zníženie klinických príznakov klasického moru ošípaných, ako aj na zníženie infekcie s a vylučovanie ssr oblasti vírus. nástup ochrany je 2 týždne. trvanie ochrany je 6 mesiacov.
cassiopee 79 wg
bayer ag - dispergovateľné granule - iprovalicarb 40 g/kg; folpet 250 g/kg; fosetyl-al 500 g/kg
cassiopee 79 wg
bayer ag - dispergovateľné granule - iprovalicarb 40 g/kg; folpet 250 g/kg; fosetyl-al 500 g/kg
blincyto
amgen europe b.v. - blinatumomab - prekurzorová bunková lymfoblastická leukémia-lymfóm - antineoplastické činidlá - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.